Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer
Laura A Baker, Holly Holliday, Daniel Roden, Christoph Krisp, Sunny Z Wu, Simon Junankar, Aurelien A Serandour, Hisham Mohammed, Radhika Nair, Geetha Sankaranarayanan, Andrew MK Law, Andrea McFarland, Peter T Simpson, Sunil Lakhani, Eoin Dodson, Christina Selinger, Lyndal Anderson, Goli Samimi, Neville F Hacker, Elgene Lim Show all
Breast Cancer Research | BMC | Published : 2020
BACKGROUND: Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the development of personalised therapeutic strategies. Inhibitor of differentiation 4 (ID4) is a helix-loop-helix transcriptional regulator required for mammary gland development. ID4 is overexpressed in a subset of BLBC patients, associating with a stem-like poor prognosis phenotype, and is necessary for the growth of cell line models of BLBC through unknown mechanisms. METHODS: Here, we have defined unique ..View full abstract
Australia Postgraduate Award (to LAB and HH), Boehringer Ingelheim Fonds, Cancer Council NSW, The National Health and Medical Research Council of Australia, The McMurtrie family, Beth Yarrow Memorial Award, Castle Harlan Award, LH Ainsworth Award and Research conducted at APAF were supported by the Australian Government's National Collaborative Research Infrastructure Scheme.